The neoadjuvant paradigm reinvigorated: a review of pre-surgical immunotherapy in HNSCC

Table 1 Active and recently posted neoadjuvant immunotherapy trials

Trial number	Phase	Neoadjuvant therapy
NCT03700905^a	III	nivolumab
NCT03765918^a	III	pembrolizumab
NCT02002182	II	ADXS11–001 (ADXS-HPV) vaccine
NCT02296684^ar	II	pembrolizumab
NCT02488759^r	I/II	nivolumab
NCT02609386^a	II	IRX-2 plus cyclophosphamide, then indomethacin, zinc-containing vitamins and omeprazole
NCT02641093^ar	II	pembrolizumab
NCT03003637^r	I/II	ipilimumab and nivolumab
NCT03021993^r	II	nivolumab
NCT03107182^a	II	nab-paclitaxel, carboplatin, nivolumab
NCT03174275^a	II	carboplatin, nab-paclitaxel, durvalumab
NCT03247712^a	I/II	nivolumab
NCT03342911	II	carboplatin, paclitaxel, nivolumab
NCT03708224^a	II	atezolizumab +/− emactuzumab
NCT03721757^a	II	nivolumab
NCT03737968^a	II	durvalumab +/− tremelimumab
NCT03916627^a	II	cemiplimab
NCT03944915	II	carboplatin, paclitaxel, and nivolumab
NCT03129061	I	carboplatin, nab-paclitaxel, durvalumab
NCT03144778^r	I	durvalumab +/− tremelimumab
NCT03635164^a	I/Ib	RT + durvalumab
NCT03843515	I	nivolumab

ISSN: 2059-7347